Trial Profile
A Pilot Study of Pembrolizumab and Exemestane/ Leuprolide in Premenopausal Hormone Receptor Positive/ HER2 Negative Locally Advanced or Metastatic Breast Cancer
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 22 May 2023
Price :
$35
*
At a glance
- Drugs Exemestane (Primary) ; Leuprorelin (Primary) ; Pembrolizumab (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms PEER
- 19 Apr 2023 Results of final analysis , presented at the 114th Annual Meeting of the American Association for Cancer Research
- 20 Feb 2023 Status changed from recruiting to discontinued.
- 06 May 2021 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.